ValuEngine upgraded shares of Amedisys (NASDAQ:AMED) from a buy rating to a strong-buy rating in a report released on Monday, February 4th.
Several other analysts have also weighed in on AMED. Cantor Fitzgerald lifted their price objective on Amedisys from $117.00 to $125.00 and gave the stock a neutral rating in a report on Thursday, October 11th. SunTrust Banks raised their target price on Amedisys to $130.00 and gave the stock a buy rating in a research report on Thursday, October 11th. Robert W. Baird raised their target price on Amedisys from $105.00 to $120.00 and gave the stock a neutral rating in a research report on Thursday, October 11th. BidaskClub downgraded Amedisys from a strong-buy rating to a buy rating in a research report on Tuesday, October 16th. Finally, Craig Hallum downgraded Amedisys from a buy rating to a hold rating and cut their target price for the stock from $116.00 to $104.00 in a research report on Friday, October 26th. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $125.55.
Shares of NASDAQ:AMED traded down $0.10 during trading on Monday, hitting $124.20. 371,868 shares of the stock were exchanged, compared to its average volume of 622,191. Amedisys has a 1-year low of $56.95 and a 1-year high of $140.91. The firm has a market capitalization of $4.11 billion, a PE ratio of 34.21, a PEG ratio of 1.70 and a beta of 1.43. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.12.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, February 27th. The health services provider reported $0.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.06. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. The company had revenue of $434.38 million for the quarter, compared to analyst estimates of $427.75 million. During the same quarter last year, the firm earned $0.56 EPS. Amedisys’s revenue for the quarter was up 9.2% compared to the same quarter last year. On average, sell-side analysts predict that Amedisys will post 4.04 EPS for the current year.
In other news, insider David L. Kemmerly sold 3,125 shares of the business’s stock in a transaction on Wednesday, December 12th. The stock was sold at an average price of $133.82, for a total transaction of $418,187.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David B. Pearce sold 410 shares of the business’s stock in a transaction on Monday, December 24th. The stock was sold at an average price of $106.61, for a total value of $43,710.10. Following the sale, the insider now owns 11,010 shares of the company’s stock, valued at approximately $1,173,776.10. The disclosure for this sale can be found here. Insiders own 2.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in AMED. First Hawaiian Bank raised its position in shares of Amedisys by 45.6% during the fourth quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock worth $49,000 after acquiring an additional 130 shares during the last quarter. Financial Gravity Companies Inc. acquired a new stake in shares of Amedisys during the fourth quarter worth $50,000. Meeder Asset Management Inc. grew its stake in shares of Amedisys by 107.4% during the fourth quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock worth $56,000 after purchasing an additional 247 shares during the period. Captrust Financial Advisors grew its stake in shares of Amedisys by 161.8% during the fourth quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock worth $70,000 after purchasing an additional 369 shares during the period. Finally, Group One Trading L.P. acquired a new stake in shares of Amedisys during the fourth quarter worth $90,000. Institutional investors own 92.15% of the company’s stock.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Article: Dividend
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.